...
首页> 外文期刊>Drug delivery. >Development and characterization of enteric-coated microparticles of biochanin A for their beneficial pharmacological potential in estrogen deficient-hypertension
【24h】

Development and characterization of enteric-coated microparticles of biochanin A for their beneficial pharmacological potential in estrogen deficient-hypertension

机译:肠溶菌素A肠溶衣微粒的开发和表征,其在雌激素缺乏高血压中的有益药理潜力

获取原文
获取原文并翻译 | 示例

摘要

Enteric coating of microparticles prevents stomach degradation and enhances oral bioavailability of poorly soluble drugs. Thus, in the present study, enteric-coated microparticle (ECMP) of biochanin A was developed and their pharmacological potential was investigated in hypertensive ovariectomized rats (Ovx-HT). Biochanin A microparticles were prepared by using ionic gelation method and coating was done by ethyl cellulose using coacervation phase separation method. Surface modified microparticles were characterized on the basis of size, entrapment efficiency, polydispersity index, FTIR and zeta potential and percentage of in vitro release. Ovariectomized rats were administered deoxy corticosterone acetate (40 mg/kg, s.c. twice a week for 6 weeks) salt to induce Ovx-HT. Hypertension was assessed in terms of increase in systolic, diastolic, mean arterial blood pressure, lipid peroxidation level, tumor necrosis factor-alpha (TNF-alpha) level and decrease in serum nitrite and reduced glutathione (GSH) level. The optimized formulation of ECMP has shown significant increase in oral bioavailability assessed by high-performance liquid chromatography. Furthermore, these ECMPs significantly reduced the mean arterial blood pressure, systolic and diastolic blood pressure, reduced lipid peroxidation and TNF-alpha level and significantly increased the serum nitrite and reduced GSH level in Ovx-HT rats. However, L-NAME significantly prevented the ameliorative effect of ECMP. Thus, it may be concluded that ECMP of biochanin A has shown delayed release capacity, increase in oral bioavailability up to 6 folds than plain biochanin A and exerts antihypertensive effect in ovariectomized rats possibly in an eNOS dependent manner.
机译:微粒的肠溶衣可防止胃部降解并提高难溶性药物的口服生物利用度。因此,在本研究中,开发了生物chanin A的肠溶衣微粒(ECMP),并研究了在去卵巢高血压大鼠(Ovx-HT)中的药理潜力。用离子凝胶法制备了生物chanin A微粒,并通过凝聚相分离法在乙基纤维素上包被。根据尺寸,截留效率,多分散指数,FTIR和ζ电位以及体外释放百分比对表面改性的微粒进行了表征。去卵巢的大鼠接受脱氧乙酸皮质酮乙酸盐(40 mg / kg,每周两次,共6周,皮下注射)盐诱导Ovx-HT。根据收缩压,舒张压,平均动脉血压,脂质过氧化水平,肿瘤坏死因子-α(TNF-α)水平升高,血清亚硝酸盐降低和谷胱甘肽(GSH)水平降低来评估高血压。通过高效液相色谱评估,ECMP的优化配方已显示出口服生物利用度的显着提高。此外,这些ECMP可显着降低Ovx-HT大鼠的平均动脉血压,收缩压和舒张压,降低脂质过氧化和TNF-α水平,并显着提高血清亚硝酸盐和GSH水平。但是,L-NAME明显阻止了ECMP的改善效果。因此,可以得出结论,生物chanin A的ECMP表现出延迟释放能力,口服生物利用度比普通biochanin A高达6倍,并且可能以eNOS依赖的方式在去卵巢大鼠中发挥降压作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号